Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus

Kabadi, Mary U.; Kabadi, Udaya M.

doi:10.1016/s0149-2918(04)90006-9

Cited by 38 publications

(42 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, therapy with SUs results in superior efficacy in lowering overall diurnal glycemia with a greater reduction in HbA1c as described previously [31]. Finally, Glimepiride induces a rise in both 1 st and 2 nd phase postprandial insulin secretion as well as improvement in insulin sensitivity and therefore appears to be more effective than other SUs [31, 52,53].…”

mentioning

confidence: 72%

New Oral Diabetes Drugs are more effective than Older Agents: Real or a Fraud?

Kabadi¹

2016

JDMDC

View full text Add to dashboard Cite

mentioning

confidence: 72%

New Oral Diabetes Drugs are more effective than Older Agents: Real or a Fraud?

Kabadi¹

2016

JDMDC

View full text Add to dashboard Cite

“…Sulfonylureas drugs have been used for the treatment of diabetes for several years. As a representative drug, sulfonylureas has been reported to inhibitor the KATP channel to promote insulin secretion [18,19]. However, sulfonylureas might cause hypoglycemia due to not dependence of blood glucose [20].…”

Section: Discussionmentioning

confidence: 99%

Insulin Secretion with the Effect of Loureirin B through K<sub>ATP </sub>Channel–Dependent Pathway

Sha¹,

Zhang²,

Cao³

et al. 2017

Preprint

View full text Add to dashboard Cite

The development of new diabetes drugs continues to be explored. Loureirin B, a flavonoid, extracted from Dracaena cochinchinensis, has been confirmed to increase insulin secretion and decrease blood glucose levels. For understanding the mechanism, a series of experiments had been employed based on computational methods and cell experiments. The insulin secretion significantly increased with the incubation of 0.01μM loureirin B for 4 hours. The viability of Ins-1 cells showed no significant difference with the treatment of loureirin B. Through computational methods, we hypothesized that loureirin B could interacts with KATP channels to promote insulin secretion. In cell experiments, it could be found that the current of KATP channel of Ins-1 cells was inhibited by the effect of loureirin B. After then, the voltage-dependent calcium channels were activated, the increase of Cx43 protein expression might mediate the Ca 2+ to the intracellular. In summary, it could be concluded that loureirin B promoted insulin secretion mainly through inhibiting KATP current, the influx of Ca 2+ to the Intracellular and the expression of Cx43.

show abstract

“…A low blood insulin/blood glucose ratio in glimepiride indicates that blood glucose is decreased without abnormal elevations in the plasma insulin levels. Glimepiride due to its additional extra pancreatic effects does not over work the β-cells and has an endogenous insulin sparing action 9 .…”

Section:  Extra Pancreatic Effectsmentioning

confidence: 99%

“…Thus, it does not overwork the β-cells. Hence, the chances of secondary failure with glimepiride are less as compared to glibenclamide 9,11 .…”

Section:  Extra Pancreatic Effectsmentioning

confidence: 99%

Untitled

2010

IJPSR

View full text Add to dashboard Cite

The prevalence of diabetes in India has been growing by leaps and bounds. The statistics in this regard are quite alarming. It is obvious that in a country like India, the rising prevalence of diabetes with its complications is likely to produce severe constraints on health care budgets in future. This explosion of diabetes in India has been viewed with serious concern by the WHO and the International Diabetes Federation (IDF). The two principal defects in type 2 diabetes are insulin deficiency and insulin resistance. Therefore, combining an insulin-providing agent with an insulin sensitizing agent will augment the efficacy of current antihyperglycaemic agents. This is the rational for the development and marketing of sulfonylurea/metformin combination tablets. The ultimate or primary goal of therapy for type 2 diabetes is to prevent the mortality and morbidity related to the microvascular and macrovascular complications. Since these disorders are life long, reduction in the number of tablets and daily doses is a very important consideration from the patient point of view. It is increasingly obvious that to achieve this on a global perspective will have to identify better and more effective treatment strategies to maintain tight glycaemic control.

show abstract

Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus

Cited by 38 publications

References 35 publications

New Oral Diabetes Drugs are more effective than Older Agents: Real or a Fraud?

New Oral Diabetes Drugs are more effective than Older Agents: Real or a Fraud?

Insulin Secretion with the Effect of Loureirin B through K<sub>ATP </sub>Channel–Dependent Pathway

Untitled

Contact Info

Product

Resources

About

Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus

Cited by 38 publications

References 35 publications

New Oral Diabetes Drugs are more effective than Older Agents: Real or a Fraud?

New Oral Diabetes Drugs are more effective than Older Agents: Real or a Fraud?

Insulin Secretion with the Effect of Loureirin B through K<sub>ATP </sub>Channel&ndash;Dependent Pathway

Untitled

Contact Info

Product

Resources

About

Insulin Secretion with the Effect of Loureirin B through K<sub>ATP </sub>Channel–Dependent Pathway